Diadeep and Leica Biosystems Partner to Bring AI Oncology Pathology Applications to the Aperio AI Store

Expanding access to integrated AI tools helps pathologists tackle complex workflows and improve insights

Lyon, France and VISTA, CA — May 27, 2026  DiaDeep, a Lyon-based company specialized in medical AI for oncology pathology, and Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced a new commercial partnership. Through this agreement, Leica Biosystems will serve as a global reseller of DiaDeep’s AI applications, making them available through the Aperio AI Store—a curated platform providing access to a wide range of advanced AI tools.

DiaDeep’s solutions will integrate seamlessly with the Aperio HALO AP image management system, enabling pathologists to access AI-powered insights within their existing digital workflows. This collaboration brings together DiaDeep’s expertise in artificial intelligence and oncology with Leica Biosystems’ extensive global footprint and leadership in digital pathology. Together, the companies aim to support the growing demand for scalable, interoperable AI solutions that can enhance workflows, improve efficiency, and support research and clinical development in pathology.

“Pathologists face growing complexity on every slide, often with less time to deliver answers,” said Sanae Salhi, CEO of DiaDeep. “We serve as their copilot, automating quantification so their expertise can focus where it has the greatest impact. This agreement helps make that possible for more pathologists.”

“We are excited to welcome DiaDeep to the growing ecosystem of AI-enabled applications available through the Aperio AI Store,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “Collaborating with innovative companies like DiaDeep enables us to combine complementary technologies, deep expertise, and global scale to help address some of the most complex challenges in pathology. By delivering integrated solutions within Aperio HALO AP software that align with real-world laboratory workflows, we can help pathologists adopt AI more seamlessly, reduce operational complexity, and drive meaningful outcomes."

This agreement highlights the increasing importance of AI in pathology and reflects a shared commitment from both organizations to advance cancer diagnostics through accessible, integrated digital solutions. By combining trusted digital pathology infrastructure with innovative AI applications, Leica Biosystems and DiaDeep are helping laboratories accelerate their adoption of next-generation technologies.

For Research Use Only. Not for Use in Diagnostic Procedures. Aperio HALO AP is CE-IVDR marked in the EU.

About DiaDeep
Founded in 2022 in Lyon, DiaDeep is a European manufacturer of in vitro diagnostic medical devices specialized in oncology. Its CE-IVDR certified, ISO 13485 compliant solutions support pathologists in the most demanding therapeutic decisions across immunotherapy, targeted therapies and hormonal therapy. DiaDeep is backed by a community of 52 pathologist physicians as shareholders, anchoring its development in real clinical practice.

About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in end-to-end anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of ‘Advancing Cancer Diagnostics, Improving Lives’ is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at www.leicabiosystems.com.

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.